@article{10902/21534,
year = {2020},
month = {6},
url = {http://hdl.handle.net/10902/21534},
abstract = {ABSTRACT: Cardiovascular (CV) disease is the main cause of mortality in axial spondyloarthritis (axSpA). CV risk is enhanced by dysregulation of adipokines. Low omentin levels were associated with metabolic dysfunction and CV disease in conditions different from axSpA. Accordingly, we evaluated the genetic and functional implication of omentin in CV risk and subclinical atherosclerosis in a cohort of 385 axSpA patients. Subclinical atherosclerosis was evaluated by carotid ultrasound. Omentin rs12409609, in linkage disequilibrium with a polymorphism associated with CV risk, was genotyped in 385 patients and 84 controls. Serum omentin levels were also determined. omentin mRNA expression was assessed in a subgroup of individuals. Serum and mRNA omentin levels were lower in axSpA compared to controls. Low serum omentin levels were related to male sex, obesity, inflammatory bowel disease (IBD) and high atherogenic index. rs12409609 minor allele was associated with low omentin mRNA expression in axSpA. No association was observed with subclinical atherosclerosis at the genetic or functional level. In conclusion, in our study low omentin serum levels were associated with CV risk factors in axSpA. Furthermore, rs12409609 minor allele may be downregulating the expression of omentin. These data support a role of omentin as a CV risk biomarker in axSpA.},
organization = {We wish to thank all the patients and controls that participated in this study. This work was supported by funds of a NEXT-VAL grant (NVAL17/10) (Instituto de Investigación Sanitaria IDIVAL) awarded to FG. SR-M is supported by funds of the RETICS Program (RD16/0012/0009) from the ‘Instituto de Salud Carlos III´ (ISCIII), co-funded by the European Regional Development Fund (ERDF). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). VM is supported by funds of a Miguel Servet type I programme (grant CP16/00033) (ISCIII, co-funded by the European Social Fund (ESF)). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the ESF (grant CP16/00033).},
publisher = {Nature Publishing Group},
publisher = {Scientific Reports 10, Article number: 9636 (2020)},
title = {Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis},
author = {Genre, Fernanda and Rueda-Gotor, Javier and Remuzgo Martínez, Sara and Pulito-Cueto, Verónica and Corrales, Alfonso and Mijares Díaz, Verónica and Lera-Gómez, Leticia and Portilla, Virginia and Expósito, Rosa and Mata, Cristina and Blanco, Ricardo and Llorca Díaz, Francisco Javier and Hernández-Hernández, Vanesa and Vicente, Esther and Fernández-Carballido, Cristina and Martínez-Vidal, María Paz and Castro-Corredor, David and Anino-Fernández, Joaquín and González-Gay Mantecón, Miguel Ángel},
}